2. Immunology/Inflammation Apoptosis
  3. Interleukin Related Apoptosis
  4. Benralizumab

Benralizumab  (Synonyms: MEDI-563; BIW-8405)

Cat. No.: HY-P9923 Purity: 99.1%
COA

Molarity Calculator

Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma.

For research use only. We do not sell to patients.

Benralizumab Chemical Structure

Benralizumab Chemical Structure

CAS No. : 1044511-01-4

Size Price Stock Quantity
1 mg USD 880 In-stock
2 mg USD 1450 In-stock
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Benralizumab:

Benralizumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma[1].

IC50 & Target[1]

IL-5Rα

 

In Vitro

Benralizumab (MEDI-563) binds to recombinant human and cynomolgus monkey IL-5Rα extracellular domains with a dissociation constant of 11 and 42 pM, respectively[2].
Benralizumab (1 pM-100 nM, 48 h) inhibits IL-5–induced proliferation of CTLL-2 cells transfected with recombinant human IL-5Rαβ with an IC50 of 0.3 nM[2].
Benralizumab binds only to the constructs containing human IL-5Rα D1[2].
Benralizumab mediates ADCC (antibody-dependent cell-mediated cytotoxicity) of human eosinophils and basophils with EC50s of 0.9 pM and 0.5 pM, respectively, and mediates eosinophil apoptosis[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Benralizumab Related Antibodies

Cell Proliferation Assay[2]

Cell Line: CTLL-2 human IL-5Rαβ cells
Concentration: 1 pM-100 nM
Incubation Time: 48 h
Result: Inhibited cell proliferation with an IC50 of 0.3 nM.
In Vivo

Benralizumab (MEDI-563) (0-30 mg/kg; i.v.; once every 3 weeks for 12 weeks) reduces peripheral blood and bone marrow eosinophil[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female and male cynomolgus monkeys[2]
Dosage: 0.1, 1, 10, and 30 mg/kg
Administration: Intravenous injection, once every 3 weeks for 12 weeks
Result: Blood eosinophil counts decreased close to the limit of detection after the first administration at all dose levels and remained undetectable. Eosinophil precursors in the bone marrow were reduced 80% or greater in all doses 3 days after the last administration (terminal necropsy) and remained undetectable until 18 days after the last dose in the 30 mg/kg group. The profound effect observed in the bone marrow was specific for the eosinophil lineage.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Benralizumab]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: ≥99.1%

COA (291 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Benralizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Benralizumab1044511-01-4MEDI-563 BIW-8405MEDI563MEDI 563BIW8405BIW 8405BIW-8405Interleukin RelatedApoptosisILeosinophilic asthmachronic obstructive pulmonary diseaseCOPDInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Benralizumab
Cat. No.:
HY-P9923
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.